Egalet Corporation (NASDAQ:EGLT)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Monday. They currently have a $7.00 target price on the specialty pharmaceutical company’s stock.

Several other equities analysts also recently weighed in on EGLT. Guggenheim set a $7.00 price target on shares of Egalet Corporation and gave the company a “buy” rating in a report on Monday. JMP Securities lowered their price target on shares of Egalet Corporation from $15.00 to $6.00 and set a “market outperform” rating on the stock in a report on Friday, July 14th. Stifel Nicolaus reaffirmed a “buy” rating and set a $6.00 price target (down previously from $14.00) on shares of Egalet Corporation in a report on Thursday. Zacks Investment Research downgraded shares of Egalet Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, May 10th. Finally, Gabelli raised shares of Egalet Corporation from a “hold” rating to a “buy” rating and set a $9.50 price target on the stock in a report on Friday, May 12th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $6.50.

Egalet Corporation (EGLT) traded up 9.7647% during mid-day trading on Monday, reaching $1.1196. 1,921,323 shares of the company were exchanged. Egalet Corporation has a one year low of $1.01 and a one year high of $10.00. The stock’s market capitalization is $48.20 million. The stock has a 50 day moving average of $1.59 and a 200-day moving average of $3.39.

Egalet Corporation (NASDAQ:EGLT) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.94) by $0.10. Egalet Corporation had a negative net margin of 444.50% and a negative return on equity of 2,190.07%. The firm had revenue of $6.26 million for the quarter, compared to analysts’ expectations of $6.68 million. During the same period in the prior year, the firm earned ($0.97) EPS. Egalet Corporation’s revenue for the quarter was up 81.4% compared to the same quarter last year. On average, equities analysts expect that Egalet Corporation will post ($2.72) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/14/egalet-corporation-eglt-stock-rating-reaffirmed-by-cantor-fitzgerald.html.

Several large investors have recently added to or reduced their stakes in EGLT. SG Americas Securities LLC boosted its stake in Egalet Corporation by 80.3% in the first quarter. SG Americas Securities LLC now owns 30,479 shares of the specialty pharmaceutical company’s stock valued at $155,000 after buying an additional 13,570 shares during the last quarter. Teachers Advisors LLC boosted its stake in Egalet Corporation by 10.1% in the fourth quarter. Teachers Advisors LLC now owns 39,984 shares of the specialty pharmaceutical company’s stock valued at $306,000 after buying an additional 3,666 shares during the last quarter. KCG Holdings Inc. boosted its stake in Egalet Corporation by 81.0% in the first quarter. KCG Holdings Inc. now owns 42,722 shares of the specialty pharmaceutical company’s stock valued at $218,000 after buying an additional 19,116 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in Egalet Corporation by 1.1% in the second quarter. Janney Montgomery Scott LLC now owns 45,963 shares of the specialty pharmaceutical company’s stock valued at $109,000 after buying an additional 500 shares during the last quarter. Finally, LMR Partners LLP bought a new stake in Egalet Corporation during the second quarter valued at about $179,000. Hedge funds and other institutional investors own 38.55% of the company’s stock.

Egalet Corporation Company Profile

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Analyst Recommendations for Egalet Corporation (NASDAQ:EGLT)

Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.